Loading the session
Loading the session
Loading instrument
$12.78
+21.98%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:06 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +2.9% (SPY −1.6%, XLV +13.5%). 3 months: +13.2% (SPY −0.4%, XLV +15.5%). 1 year: −28.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ADMA, SPY and XLV · as of 4 Nov 2026
4 Nov 2026 volume of 13.4M shares was 4.6× the average of the 30 sessions before it (2.9M), as the price fell 5.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
The 4 Nov 2026 close of $10.48 was 4.1% above its 50-day average ($10.07) and 3.5% below its 200-day average ($10.86). It has closed below the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed below the 200-day on 27 Feb 2026, 173 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
19.5M shares were sold short at the 15 Oct 2026 settlement, 8.7% of the 224.0M shares outstanding; covering them would take 6.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Closed at $10.48 on 4 Nov 2026: 48.8% below the 52-week high of $20.46 (12 Dec 2025) and 40.7% above the low of $7.45 (2 Jun 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
August 9, 2024
+30.93%May 10, 2024
+27.13%November 10, 2022
+27.53%